InvestorsKeyhole Upgrades & Downgrades

Seattle Genetics (SGEN) Stock Upgraded to Overweight

Analysts at Piper Jaffray raised their rating on shares of Seattle Genetics (SGEN) stock from “Neutral” to “Overweight” on Wednesday.

Already a member?

Login to see your Upgrades And Downgrades Trade Idea.

Not yet a member?

You can receive four timely bull-put credit spreads each market day by joining our InvestorsKeyhole Daily Trade Alerts Service. Our analysts scour the news looking for unusual options activity, how insiders are trading, and breaking news, and publish trades accordingly.

Become A Member

SGEN
About Seattle Genetics Inc.

Seattle Genetics is a biotech firm focused on the development of monoclonal antibody-based therapies. The company's lead product, Adcetris, has received approval for advanced frontline, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. The company has several other early-stage programs in trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Download this step-by-step guide on placing InvestorsKeyhole Daily Trade Alerts.

How to place a credit spread

How to place a vertical debit spread

|

You May Also Like